Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_2
1
33%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

completed267%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_4

Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome

NCT02986750
unknownphase_2

Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy

NCT03575130
completednot_applicable

Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular Dryness

NCT03517748

Clinical Trials (3)

Showing 3 of 3 trials
NCT02986750Phase 4

Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome

Completed
NCT03575130Phase 2

Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy

Unknown
NCT03517748Not Applicable

Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular Dryness

Completed

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3